We are live on ! Find out more
LFCR icon

Lifecore Biomedical

101 hedge funds and large institutions have $302M invested in Lifecore Biomedical in 2014 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 35 increasing their positions, 39 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

50% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 6

14% more capital invested

Capital invested by funds: $265M → $302M (+$36.7M)

3% more funds holding

Funds holding: 98101 (+3)

10% less repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 39

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $275K

Holders
101
Holders Change
+3
Holders Change %
+3.06%
% of All Funds
2.9%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.06%
New
9
Increased
35
Reduced
39
Closed
6
Calls
Puts
$275K
Net Calls
-$275K
Net Calls Change
-$133K
Name Holding Trade Value Shares
Change
Change in
Stake
PNC Financial Services Group
101
PNC Financial Services Group
Pennsylvania
$1K
Principal Financial Group
102
Principal Financial Group
Iowa
-$1.67M -149,600 Closed
BMCMI
103
Bryn Mawr Capital Management Inc
Pennsylvania
-$445K -39,895 Closed
Allianz Asset Management
104
Allianz Asset Management
Germany
-$357K -32,029 Closed
BAM
105
Barrett Asset Management
New York
-$11K -1,000 Closed
Group One Trading
106
Group One Trading
Illinois
-$10K -892 Closed

LFCR Hedge Fund Activity: Q2 2014 in Review

101 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Lifecore Biomedical (LFCR) for Q2 2014, worth a combined $302M — up 14% from $265M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new LFCR positions and 6 closed out — a net gain of 3 holders — while 35 added to existing stakes and 39 trimmed.

The largest buyer was Royce & Associates, adding an estimated $3.59M. The largest seller was Opus Capital Group, cutting an estimated $1.85M.

  • 101 institutional investors held Lifecore Biomedical (LFCR) as of Q2 2014, up from 98 in Q1 2014.
  • Funds reported $302M of Lifecore Biomedical stock for Q2 2014, up 14% quarter-over-quarter.
  • 9 funds opened new Lifecore Biomedical positions in Q2 2014 and 6 closed out, a net change of +3 holders.
  • The largest Lifecore Biomedical buyer in Q2 2014 was Royce & Associates, an estimated $3.59M added.
  • The largest Lifecore Biomedical seller in Q2 2014 was Opus Capital Group, an estimated $1.85M sold.

Based on aggregated 13F filings for Q2 2014.